Dr. Nuria Bermejo Vega is a highly experienced medical specialist in Hematology with extensive expertise in thrombosis, hemostasis, and platelet disorders. As a Facultativo Especialista de Área at the Servicio Extremeño de Salud, her research and clinical work focus on bleeding and thrombotic disorders, hemophilia, and the molecular mechanisms underlying hematological diseases. She has actively contributed to numerous national and international research projects and clinical trials in collaboration with major scientific and pharmaceutical institutions such as the International Society on Thrombosis and Haemostasis (ISTH), Fundación Fundesalud, Novo Nordisk, Pfizer, Bayer, and Grifols. Her participation in multicenter studies has advanced knowledge in platelet physiology, calcium signaling in cancer cells, and genetic-molecular diagnosis of coagulation disorders. Dr. Bermejo’s research has played a crucial role in standardizing diagnostic tools, evaluating new therapeutic approaches, and improving patient care for rare hematological diseases. She has also been involved in projects supported by the Spanish Ministry of Science and Innovation and the Ministry of Economy and Competitiveness, addressing molecular pathways and pharmacological interventions in platelet and vascular dysfunctions. Her scientific dedication and clinical insight contribute significantly to the advancement of hematology and translational research in Spain.
Profiles: Scopus | Orcid | Google Scholar
Featured Publications
González-López, T. J., Bermejo-Vega, N., Cardesa-Cabrera, R., Martínez-Robles, V., Aguilar-Monserrate, G., Pérez-Segura, G., Domingo, A., Luis-Navarro, J., Lakhwani, S., Acedo, N., et al. (2024). Fostamatinib effectiveness and safety for immune thrombocytopenia in clinical practice. Blood.
Bermejo, N., Casado-Cabanillas, V., González-Valero, J., Higuero, V., & Espacio, F. (2023). PB2665: Thrombotic profile of a serie of 14 patients carrying 67Arg>Stop polymorphism in the SERPINE A10 (protease-dependent protein Z inhibitor) gene. HemaSphere, 7(Supplement 1).
Alessi, M. C., Coxon, C., Ibrahim-Kosta, M., Bacci, M., Voisin, S., Rivera, J., Greinacher, A., Raster, J., Pulcinelli, F., Devreese, K. M. J., et al. (2023). Multicenter evaluation of light transmission platelet aggregation reagents: Communication from the ISTH SSC Subcommittee on Platelet Physiology. Journal of Thrombosis and Haemostasis (JTH).
Lozano, M. L., Mingot-Castellano, M. E., Perera, M. M., Jarque, I., Campos-Álvarez, R. M., González-López, T. J., Carreño-Tarragona, G., Bermejo, N., López-Fernández, M. F., & Vicente, V. (2021). Author correction: Deciphering predictive factors for choice of thrombopoietin receptor agonist, treatment-free responses, and thrombotic events in immune thrombocytopenia. Scientific Reports, 11(1).
Palma-Barqueros, V., Crescente, M., de la Morena, M. E., Chan, M. V., Almarza, E., Revilla, N., Bohdan, N., Miñano, A., Padilla, J., Allan, H. E., et al. (2021). A novel genetic variant in PTGS1 affects N-glycosylation of cyclooxygenase-1 causing a dominant-negative effect on platelet function and bleeding diathesis. American Journal of Hematology, 96(2), E33–E37.